Sangdeep Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 4.40 Cr
as on 17-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 31.50 Cr
as on 17-12-2024
- Satisfied Charges ₹ 2.40 Cr
as on 17-12-2024
- Revenue %
(FY 2022)
- Profit -211.40%
(FY 2022)
- Ebitda -216.25%
(FY 2022)
- Net Worth -3.76%
(FY 2022)
- Total Assets 30.23%
(FY 2022)
About Sangdeep Pharmachem
The Corporate was formerly known as Sangdeep Oilfield Chemicals Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.40 Cr.
The company currently has active open charges totaling ₹31.50 Cr. The company has closed loans amounting to ₹2.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Neel Shah, Sandeep Shah, and Sagar Shah serve as directors at the Company.
- CIN/LLPIN
U24233GJ2014PTC080556
- Company No.
080556
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Aug 2014
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sangdeep Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neel Shah  | Director | 22-Aug-2014 | Current |
| Sandeep Shah | Director | 22-Aug-2014 | Current |
| Sagar Shah | Additional Director | 18-Aug-2023 | Current |
Financial Performance of Sangdeep Pharmachem.
Sangdeep Pharmachem Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 211.4% decrease in profit. The company's net worth dipped by a decrease of 3.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sangdeep Pharmachem?
In 2021, Sangdeep Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Sep 2022 | ₹15.75 Cr | Open |
Others Creation Date: 29 Jul 2022 | ₹15.75 Cr | Open |
Hdfc Bank Limited Creation Date: 20 Apr 2021 | ₹2.40 Cr | Satisfied |
How Many Employees Work at Sangdeep Pharmachem?
Unlock and access historical data on people associated with Sangdeep Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sangdeep Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sangdeep Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
